Table 1 Association between (P) RR expression levels in primary colorectal tumors and clinicopathological characteristics
From: The (pro)renin receptor: a novel biomarker and potential therapeutic target for various cancers
Case number | (P) RR expression level (Immunohistochemistry) | Constituent ratio difference | ||||
|---|---|---|---|---|---|---|
Weak | Middle | Strong | Pvalue | χ2 | ||
Case number (percentage) | ||||||
Gender | 60 | |||||
Male | 31 | 4 (12%) | 15 (47%) | 13 (41%) | < 0.0001*** | 27.36 |
Female | 28 | 9 (32%) | 16 (57%) | 13 (11%) | ||
Onset age | 60 | |||||
<60 | 12 | 1 (8%) | 7 (59%) | 4 (33%) | 0.005** | 10.6 |
≥ 60 | 48 | 12 (25%) | 24 (50%) | 12 (25%) | ||
WHO Grade of cancer differentiation | 60 | |||||
Grade 1 | 17 | 5 (29%) | 11 (65%) | 1 (6%) | < 0.0001*** | 77.56 |
Grade 2 | 30 | 7 (23%) | 16 (53%) | 7 (23%) | ||
Grade 3 | 13 | 1 (8%) | 4 (31%) | 8 (61%) | ||
UICC Stage | 60 | |||||
Stage II | 20 | 9 (45%) | 8 (40%) | 3 (15%) | < 0.0001*** | 65.5 |
Stage III | 20 | 3 (15%) | 13 (65%) | 4 (20%) | ||
Stage IV | 20 | 1 (5%) | 10 (50%) | 9 (45%) | ||
Distant Metastasis and/or Progression after radical operation | 60 | |||||
No | 23 | 5 (22%) | 14 (61%) | 4 (17%) | 0.0352* | 6.695 |
Yes | 37 | 8 (22%) | 17 (46%) | 12 (32%) | ||
Five-year survival (patients who finished the 5-year follow-up or died within 5 years) | 47 | |||||
Yes | 25 | 5 (20%) | 13 (52%) | 7 (28%) | 0.0358 * | 6.661 |
No | 22 | 2 (9%) | 11 (50%) | 9 (41%) | ||
Recurrence-free survival time (duration from radical operation to recurrence) (months) (20 cases who had recurrence after radical operation) | ||||||
(P) RR expression level | Pvalue | χ2 | Hazard radio | 95% CI | ||
Week/Middle (16 cases) | Strong (4 cases) | |||||
10.4 | 5.85 | 0.0064** | 7.438 | 0.06804 | 0.00986–0.4695 | |